Table 3.
Characteristics of antidepressant or BDZ/Z-drug use.
| Classification of adjunctive drugs | Success group (n = 79) | Failure group (n = 91) | p-value |
|---|---|---|---|
| Use of antidepressant, N (%) | |||
| Mirtazapine | 39 (49.4) | 36 (39.6) | 0.218 |
| Duloxetine | 4 (5.1) | 11 (12.1) | 0.174 |
| Venlafaxine | 3 (3.8) | 1 (1.1) | 0.339 |
| Desvenlafaxine | 9 (11.4) | 4 (4.4) | 0.146 |
| Vortioxetine | 8 (10.1) | 4 (4.4) | 0.229 |
| Escitalopram | 24 (30.4) | 25 (49.5) | 0.013 |
| Fluoxetine | 2 (2.5) | 1 (1.1) | 0.598 |
| Paroxetine | 8 (10.1) | 8 (8.8) | 0.798 |
| Antidepressant classification, N (%) | 0.107 | ||
| NaSSA | 38 (48.1) | 36 (39.6) | 0.281 |
| SSRI | 21 (26.6) | 40 (44.0) | 0.052 |
| SNRI | 9 (11.4) | 8 (8.8) | 0.616 |
| others | 11 (13.9) | 7 (7.7) | 0.218 |
| Use of BDZ/Z-drug, N (%) | 0.277 | ||
| Alprazolam | 18 (22.8) | 20 (22.2) | 0.900 |
| Lorazepam | 27 (34.2) | 30 (33.0) | 0.872 |
| Zolpidem | 16 (20.3) | 9 (9.9) | 0.081 |
| Etizolam | 6 (7.6) | 7 (7.7) | 0.981 |
| Diazepam | 1 (1.3) | 1 (1.1) | 0.920 |
| Clonazepam | 11 (13.9) | 24 (26.4) | 0.057 |
| BDZ/Z-drug classification, N (%) | 0.959 | ||
| Anxiolytics | 45 (57.0) | 50 (54.9) | 0.877 |
| Hypnotics | 27 (34.2) | 33 (36.3) | 0.872 |
| Others | 7 (8.9) | 8 (8.8) | 0.987 |
NaSSA, Noradrenergic and specific serotonergic antidepressant; SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin-norepinephrine reuptake inhibitor.
*p < 0.0024(0.05/21). Bonferroni correction for multiple comparison